Enimmune Past Earnings Performance
Past criteria checks 0/6
Enimmune's earnings have been declining at an average annual rate of -27.2%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 48.3% per year.
Key information
-27.2%
Earnings growth rate
-15.7%
EPS growth rate
Biotechs Industry Growth | 12.2% |
Revenue growth rate | 48.3% |
Return on equity | -55.1% |
Net Margin | -514.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Enimmune makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 43 | -224 | 81 | 139 |
30 Sep 23 | 76 | -197 | 75 | 151 |
30 Jun 23 | 109 | -170 | 68 | 164 |
31 Mar 23 | 149 | -209 | 64 | 206 |
31 Dec 22 | 188 | -248 | 60 | 247 |
30 Sep 22 | 170 | -219 | 54 | 209 |
30 Jun 22 | 151 | -190 | 47 | 170 |
31 Mar 22 | 131 | -118 | 45 | 112 |
31 Dec 21 | 110 | -47 | 43 | 55 |
30 Sep 21 | 91 | -53 | 41 | 60 |
30 Jun 21 | 73 | -60 | 39 | 65 |
31 Mar 21 | 48 | -67 | 35 | 62 |
31 Dec 20 | 23 | -74 | 32 | 59 |
30 Sep 20 | 12 | -67 | 28 | 54 |
30 Jun 20 | 1 | -60 | 24 | 49 |
31 Mar 20 | 2 | -59 | 23 | 49 |
31 Dec 19 | 2 | -57 | 23 | 50 |
30 Sep 19 | 2 | -76 | 21 | 66 |
30 Jun 19 | 1 | -95 | 19 | 82 |
31 Mar 19 | 1 | -98 | 16 | 87 |
31 Dec 18 | 1 | -101 | 13 | 92 |
30 Sep 18 | 2 | -77 | 11 | 70 |
30 Jun 18 | 2 | -54 | 10 | 48 |
31 Mar 18 | 2 | -44 | 10 | 37 |
31 Dec 17 | 2 | -34 | 9 | 27 |
30 Sep 17 | 2 | -31 | 9 | 25 |
30 Jun 17 | 2 | -28 | 9 | 23 |
31 Mar 17 | 2 | -47 | 9 | 42 |
31 Dec 16 | 2 | -66 | 8 | 61 |
30 Sep 16 | 2 | -67 | 8 | 62 |
30 Jun 16 | 2 | -68 | 7 | 62 |
31 Mar 16 | 1 | -56 | 6 | 50 |
31 Dec 15 | 1 | -43 | 6 | 38 |
Quality Earnings: 6564 is currently unprofitable.
Growing Profit Margin: 6564 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6564 is unprofitable, and losses have increased over the past 5 years at a rate of 27.2% per year.
Accelerating Growth: Unable to compare 6564's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6564 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 6564 has a negative Return on Equity (-55.1%), as it is currently unprofitable.